Recent Company News

• 02:16 AM ET Oct 16, 2026
  

  Galderma Group reinstated buy at Citi; prior rating was buy (CHF 172.15, 0.00)

• 01:11 AM ET Oct 15, 2026
  

  Galderma Group announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe atopic dermatitis, sustained through Week 52 (CHF 171.85, 0.00)

• 02:29 AM ET Oct 14, 2026
  

  European macro headlines:

• 01:07 AM ET Oct 14, 2026
  

  Galderma Group to acquire ZO Skin Health for an enterprise value of $1.5B (CHF 167.35, 0.00)

• 05:19 PM ET Oct 09, 2026
  

  Bambusa Therapeutics, Inc files for Nasdaq IPO of indeterminate size - S-1

• 01:10 AM ET Oct 08, 2026
  

  Galderma Group announces new data regarding the use of Nemluvio for atopic dermatitis and prurigo nodularis (CHF 162.60, 0.00)

• 01:04 AM ET Sep 30, 2026
  

  Galderma's New Data Show Sustained Improvements with Nemluvio (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis (CHF 165.85, 0.00)

• 01:05 AM ET Sep 23, 2026
  

  Galderma Group to present 19 abstracts, including two oral presentations, at the 2026 EADV Congress, with new data on skin diseases and skin longevity (CHF 163.80, 0.00)

• 01:01 AM ET Sep 21, 2026
  

  Galderma begins trading in the Swiss Market Index (CHF 158.15, 0.00)

• 06:34 AM ET Aug 11, 2026
  

  Energy, tech and healthcare the top gainers; insurance, food/beverage and travel the main laggards: